Eli Lilly & Co.'s efforts to take on rivals Pfizer Inc. and Novartis AG in the lucrative cyclin-dependent kinase (CDK) 4/6 inhibitor space for advanced breast cancer have gotten another positive boost.
The company announced positive preliminary efficacy data from an interim analysis of the MONARCH 3 trial, showing a statistically significant improvement in progression-free survival in patients treated with abemaciclib in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?